

size of the active ingredient and rheological properties of the dosage form. In most cases, IVR rate is a useful test to assess product sameness between pre-change and post-change semisolid products. The TCS classification can help in reducing regulatory burden and help ease approval of generic drug products.

REFERENCES

1. Guidance for Industry: SUPAC-SS Nonsterile Semisolid Dosage Forms. Scale-Up and Post-approval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, May 1997.
2. Van Buskirk GA, Shah VP, Adair D, et. al., Workshop report: scale-up of liquid and semisolid disperse systems. *Pharm Res* 1994; 11:1216–1220.
3. Flynn GL, Shah VP, Tanjarla SN, et. al., Workshop report: assessment of value and applications of in vitro testing of topical dermatological drug products. *Pharm Res* 1999; 16:1325–1330.
4. USP General Chapters <3>, <1724> and <724>.
5. FDA Draft Guidance on Acyclovir Ointment 0.05%, March 2012.
6. FDA Draft Guidance on Cyclosporine Emulsions/Ophthalmic, June 2013.
7. VP Shah, A Yacobi, FS Radulescu, et. al.. A science based approach to topical drug classification system (TCS). *Int J Pharmaceutics* 2015; 491:21–25.
8. VP Shah, FS Radulescu, DS Miron, et. al.. Commonality between BCS and TCS. *Int J Pharmaceutics* 2016; 509:35–40.